Europe Biosimilars Market
The Europe Biosimilars Market size was valued at US$ 10,344.86 Mn in 2022 and is projected to reach US$ 1,15,125.91 Mn by 2030, growing at a CAGR of 35.1% during 2022 - 2030.
Report Coverage
- Disease Indication: Cancer, Diabetes, Autoimmune Disease, Other Disease Indication
- Route of Administration: Intravenous, Subcutaneous
- Drug Class: Granulocyte Colony-Stimulating Factor, Insulin, TNF Blockers and Monoclonal Antibodies
- Distribution Channel: Hospital Pharmacies, Compounding Pharmacies, Retail Pharmacies, Online
US$ 10,344.86 Mn
Market size in 2022
US$ 1,15,125.91 Mn
Market Size by 2030
35.1%
CAGR, 2022 - 2030
2023-2030
Forecast Period
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Europe Biosimilars Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Europe Biosimilars Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Europe Biosimilars Market Regional Analysis
6.2 Europe Biosimilars Market Revenue 2020-2030 (US$ Million)
6.3 Europe Biosimilars Market Forecast Analysis
7. Europe Biosimilars Market Analysis – by Disease Indication
7.1 Cancer
- 7.1.1 Overview
- 7.1.2 Cancer: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)
7.2 Diabetes
- 7.2.1 Overview
- 7.2.2 Diabetes: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)
7.3 Autoimmune Disease
- 7.3.1 Overview
- 7.3.2 Autoimmune Disease: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)
7.4 Other Disease Indication
- 7.4.1 Overview
- 7.4.2 Other Disease Indication: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)
8. Europe Biosimilars Market Analysis – by Route of Administration
8.1 Intravenous
- 8.1.1 Overview
- 8.1.2 Intravenous: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)
8.2 Subcutaneous
- 8.2.1 Overview
- 8.2.2 Subcutaneous: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)
9. Europe Biosimilars Market Analysis – by Drug Class
9.1 Granulocyte Colony-Stimulating Factor
- 9.1.1 Overview
- 9.1.2 Granulocyte Colony-Stimulating Factor: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)
9.2 Insulin
- 9.2.1 Overview
- 9.2.2 Insulin: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)
9.3 TNF Blockers and Monoclonal Antibodies
- 9.3.1 Overview
- 9.3.2 TNF Blockers and Monoclonal Antibodies: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)
10. Europe Biosimilars Market Analysis – by Distribution Channel
10.1 Hospital Pharmacies
- 10.1.1 Overview
- 10.1.2 Hospital Pharmacies: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)
10.2 Compounding Pharmacies
- 10.2.1 Overview
- 10.2.2 Compounding Pharmacies: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)
10.3 Retail Pharmacies
- 10.3.1 Overview
- 10.3.2 Retail Pharmacies: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)
10.4 Online
- 10.4.1 Overview
- 10.4.2 Online: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)
11. Europe Biosimilars Market – Europe Analysis
11.1 Overview
11.2 Europe- 11.2.1 Europe Biosimilars Market Breakdown, by Key Country, 2023 and 2030 (%)
- 11.2.1.1 Europe Biosimilars Market – Revenue and Forecast Analysis – by Country
- 11.2.1.1 UK: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
- 11.2.1.1.1 UK: Europe Biosimilars Market Breakdown, by Disease Indication
- 11.2.1.1.2 UK: Europe Biosimilars Market Breakdown, by Route of Administration
- 11.2.1.1.3 UK: Europe Biosimilars Market Breakdown, by Drug Class
- 11.2.1.1.4 UK: Europe Biosimilars Market Breakdown, by Distribution Channel
- 11.2.1.2 Germany: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
- 11.2.1.2.1 Germany: Europe Biosimilars Market Breakdown, by Disease Indication
- 11.2.1.2.2 Germany: Europe Biosimilars Market Breakdown, by Route of Administration
- 11.2.1.2.3 Germany: Europe Biosimilars Market Breakdown, by Drug Class
- 11.2.1.2.4 Germany: Europe Biosimilars Market Breakdown, by Distribution Channel
- 11.2.1.3 France: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
- 11.2.1.3.1 France: Europe Biosimilars Market Breakdown, by Disease Indication
- 11.2.1.3.2 France: Europe Biosimilars Market Breakdown, by Route of Administration
- 11.2.1.3.3 France: Europe Biosimilars Market Breakdown, by Drug Class
- 11.2.1.3.4 France: Europe Biosimilars Market Breakdown, by Distribution Channel
- 11.2.1.4 Russia: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
- 11.2.1.4.1 Russia: Europe Biosimilars Market Breakdown, by Disease Indication
- 11.2.1.4.2 Russia: Europe Biosimilars Market Breakdown, by Route of Administration
- 11.2.1.4.3 Russia: Europe Biosimilars Market Breakdown, by Drug Class
- 11.2.1.4.4 Russia: Europe Biosimilars Market Breakdown, by Distribution Channel
- 11.2.1.5 Italy: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
- 11.2.1.5.1 Italy: Europe Biosimilars Market Breakdown, by Disease Indication
- 11.2.1.5.2 Italy: Europe Biosimilars Market Breakdown, by Route of Administration
- 11.2.1.5.3 Italy: Europe Biosimilars Market Breakdown, by Drug Class
- 11.2.1.5.4 Italy: Europe Biosimilars Market Breakdown, by Distribution Channel
- 11.2.1.6 Rest of Europe: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
- 11.2.1.6.1 Rest of Europe: Europe Biosimilars Market Breakdown, by Disease Indication
- 11.2.1.6.2 Rest of Europe: Europe Biosimilars Market Breakdown, by Route of Administration
- 11.2.1.6.3 Rest of Europe: Europe Biosimilars Market Breakdown, by Drug Class
- 11.2.1.6.4 Rest of Europe: Europe Biosimilars Market Breakdown, by Distribution Channel
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 Amgen Inc
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Celltrion Inc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Sanofi SA
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Biocon Ltd,
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Samsung Bioepis Co Ltd
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Elli Lilly and Co
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Sandoz AG
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Teva Pharmaceitical Industries Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Pfizer Inc
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Dr. Reddy's Laboratories Ltd
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations
Access the Full E Market Report
Get segment-level forecasts, regional estimates, competitive benchmarking, company profiles and downloadable Excel datasets.
